IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines

October 2021 | Volume 20 | Issue 10 | Original Article | 1052 | Copyright © October 2021


Published online September 28, 2021

Martina Kerscher MD PhD,a Sabrina Fabi MD,b Tanja Fischer MD PhD,c Michael Gold MD,d John Joseph MD,e Welf Prager MD,f Berthold Rzany MD ScM,g Steve Yoelin MD,h Susanna Roll Dr. med,i Gudrun Klein PhD,i Corey Maas MD PhDj

aUniversit t Hamburg, Hamburg, Germany
bCosmetic Laser Dermatology, San Diego, CA
cHaut- & Lasercentrum, Potsdam, Germany
dGold Skin Care Center, Tennessee Clinical Research Center, Nashville, TN
eJohn Joseph MD, Private Practice, Beverly Hills, CA
fPrager and Partner Dermatologische Praxis, Hamburg, Germany
gHaut rzte RZANY&HUND, Berlin, Germany
hMedical Associates, Inc., Newport Beach, CA
iMerz Pharmaceuticals GmbH, Frankfurt am Main, Germany
jThe Maas Clinic, San Francisco, CA

RESULTS

Participants A total of 241 subjects were randomized to receive either 20U (stage 1:N=30; stage 2:N=31), 50U (stage 1:N=60), 75U (stage 1: N=61), or 100U (stage 2:N=59) INCO (Table 1). In total, 229 (95.0%) of the 241 randomized subjects completed the study. No subjects discontinued due to AEs or lack of efficacy (Figure 1). All 241 randomized subjects were included in the SES and the FAS.
Close Menu